Francois Natt
Overview
Explore the profile of Francois Natt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
1698
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cuenoud B, Casset F, Husken D, Natt F, Wolf R, Altmann K, et al.
Angew Chem Int Ed Engl
. 2018 May;
37(9):1288-1291.
PMID: 29711228
Simultaneous interaction of the 2'-aminoethoxy-modified oligonucleotides with the phosphodiester backbone (shown on the right, A) and with the bases through Hoogsteen base contacts (B) is seen at each base-pair step...
2.
Lozach F, Christensen J, Faller T, van de Kerkhof E, Krauser J, Garnier M, et al.
Pharmacol Res Perspect
. 2016 Mar;
4(1):e00209.
PMID: 26977299
The chemical modification 2'-O-methyl of nucleosides is often used to increase siRNA stability towards nuclease activities. However, the metabolic fate of modified nucleosides remains unclear. Therefore, the aim of this...
3.
Christensen J, Litherland K, Faller T, van de Kerkhof E, Natt F, Hunziker J, et al.
Drug Metab Dispos
. 2014 Jan;
42(3):431-40.
PMID: 24389421
Absorption, distribution, metabolism, and excretion properties of a small interfering RNA (siRNA) formulated in a lipid nanoparticle (LNP) vehicle were determined in male CD-1 mice following a single intravenous administration...
4.
Christensen J, Litherland K, Faller T, van de Kerkhof E, Natt F, Hunziker J, et al.
Drug Metab Dispos
. 2013 Mar;
41(6):1211-9.
PMID: 23524663
Absorption, distribution, metabolism, and excretion properties of two unformulated model short interfering RNA (siRNAs) were determined using a single internal [(3)H]-radiolabeling procedure, in which the full-length oligonucleotides were radiolabeled by...
5.
Fumagalli S, Di Cara A, Neb-Gulati A, Natt F, Schwemberger S, Hall J, et al.
Nat Cell Biol
. 2009 Mar;
11(4):501-8.
PMID: 19287375
Impaired ribosome biogenesis is attributed to nucleolar disruption and diffusion of a subset of 60S ribosomal proteins, particularly ribosomal protein (rp)L11, into the nucleoplasm, where they inhibit MDM2, leading to...
6.
Senechal Y, Prut L, Kelly P, Staufenbiel M, Natt F, Hoyer D, et al.
Brain Res
. 2008 Oct;
1243:124-33.
PMID: 18823960
Genetic abnormalities in amyloid precursor protein (APP) are associated with Down's syndrome and familial Alzheimer's disease where hallmark plaques contain A beta peptides derived from APP. Both APP and its...
7.
Gulati P, Gaspers L, Dann S, Joaquin M, Nobukuni T, Natt F, et al.
Cell Metab
. 2008 May;
7(5):456-65.
PMID: 18460336
Excess levels of circulating amino acids (AAs) play a causal role in specific human pathologies, including obesity and type 2 diabetes. Moreover, obesity and diabetes are contributing factors in the...
8.
Rines D, Gomez-Ferreria M, Zhou Y, DeJesus P, Grob S, Batalov S, et al.
Genome Biol
. 2008 Feb;
9(2):R44.
PMID: 18302737
Background: The mitotic spindle is a complex mechanical apparatus required for accurate segregation of sister chromosomes during mitosis. We designed a genetic screen using automated microscopy to discover factors essential...
9.
Leupin O, Kramer I, Collette N, Loots G, Natt F, Kneissel M, et al.
J Bone Miner Res
. 2007 Aug;
22(12):1957-67.
PMID: 17696759
Unlabelled: Expression of the osteocyte-derived bone formation inhibitor sclerostin in adult bone requires a distant enhancer. We show that MEF2 transcription factors control this enhancer and mediate inhibition of sclerostin...
10.
Natt F
Curr Opin Mol Ther
. 2007 Jul;
9(3):242-7.
PMID: 17608022
'Omics' technologies, combined with knowledge management, have changed the way pharmaceutical companies approach drug discovery activities. The rapid generation of more reliable putative drug targets from gain- or loss-of-function genome...